| P50 | author | Lukas Radbruch | Q15450815 |
| P2093 | author name string | Frank Elsner | |
| P2860 | cites work | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. | Q44843017 |
| | The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion | Q44843437 |
| | Peripheral nerve injury sensitizes the response to visceral distension but not its inhibition by the antidepressant milnacipran | Q44860924 |
| | Synergistic interactions of endogenous opioids and cannabinoid systems | Q44867023 |
| | Pharmacological characterization of the chronic constriction injury model of neuropathic pain | Q44894269 |
| | A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran | Q44977892 |
| | The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol | Q45112051 |
| | One-year chromaffin cell allograft survival in cancer patients with chronic pain: morphological and functional evidence | Q47908933 |
| | Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats | Q48462929 |
| | The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord | Q48800235 |
| | Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone | Q48968140 |
| | Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. | Q50933253 |
| | Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. | Q52535137 |
| | A fusion protein of conotoxin MVIIA and thioredoxin expressed in Escherichia coli has significant analgesic activity. | Q54516284 |
| | Traitement des douleurs post-zostériennes par le tramadol | Q56210679 |
| | The neurobiology and evolution of cannabinoid signalling | Q24522320 |
| | Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review | Q24607880 |
| | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| | Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs | Q24672983 |
| | Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801 | Q24673352 |
| | Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents | Q28178485 |
| | Nitric oxide-releasing NSAIDs: a review of their current status | Q28190519 |
| | Does nociceptin play a role in pain disorders in man? | Q28221363 |
| | An analgesia circuit activated by cannabinoids | Q28284331 |
| | Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain | Q28364765 |
| | The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain | Q28366593 |
| | Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study | Q31454905 |
| | The role of the N-methyl-D-aspartate receptor NR1 subunit in peripheral nerve injury-induced mechanical allodynia, glial activation and chemokine expression in the mouse | Q33200505 |
| | Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics | Q33745938 |
| | Antidepressant Use in Chronic Pain Management: Is There Evidence of a Role for Duloxetine? | Q33778992 |
| | Use of radionuclides for the palliation of bone metastases | Q33869335 |
| | Molecular mechanisms of cancer pain | Q33958925 |
| | Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists--in vitro characterisation. | Q34057286 |
| | Cellular and neurochemical remodeling of the spinal cord in bone cancer pain | Q34094107 |
| | Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders | Q34123860 |
| | Opioid rotation for toxicity reduction in terminal cancer patients | Q34305300 |
| | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study | Q34323910 |
| | Vanilloid receptor ligands: hopes and realities for the future | Q34391988 |
| | A potent and selective endogenous agonist for the mu-opiate receptor | Q34420509 |
| | Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo (3.2.1.) octane derivates with selective mu opioid receptor affinity | Q34449608 |
| | The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated | Q34450876 |
| | Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care | Q34539972 |
| | Renal failure associated with the use of celecoxib and rofecoxib | Q34716897 |
| | GABA-ergic drugs: exit stage left, enter stage right | Q35180791 |
| | Is noradrenaline a significant factor in the analgesic effect of antidepressants? | Q35569160 |
| | Opioid Therapy for Chronic Pain | Q35582306 |
| | The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies | Q35668146 |
| | Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic | Q35760394 |
| | Intrathecal ziconotide for refractory pain | Q35814478 |
| | The second generation of COX-2 inhibitors: clinical pharmacological point of view | Q35848209 |
| | Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. | Q35871934 |
| | Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases | Q36648239 |
| | Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway | Q37074756 |
| | Pharmacological characterization of AR-M1000390 at human delta opioid receptors | Q38352343 |
| | Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer | Q39380785 |
| | Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain | Q39381086 |
| | COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. | Q39382907 |
| | Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain | Q39391430 |
| | Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial | Q39394158 |
| | Dextromethorphan mitigates phantom pain in cancer amputees | Q39396233 |
| | Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. | Q39402924 |
| | Buprenorphine in a transdermal therapeutic system--a new option | Q39408256 |
| | A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer | Q39415661 |
| | The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study | Q39432280 |
| | Topical capsaicin in the management of HIV-associated peripheral neuropathy | Q39432518 |
| | The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial | Q39448427 |
| | Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain | Q39457109 |
| | Ketamine injection used orally | Q39464086 |
| | The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain | Q39565180 |
| | Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. | Q39673504 |
| | In their own words: Seven advanced cancer patients describe their experience with pain and the use of opioid drugs | Q39680046 |
| | Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro | Q40508560 |
| | GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization | Q40558217 |
| | Stressor-induced alterations of immune function: mechanisms and issues | Q40628177 |
| | Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor | Q40864660 |
| | Divers pathways mediate delta-opioid receptor down regulation within the same cell | Q41918324 |
| | Opposite nociceptive effects of the arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissues | Q41978727 |
| | Development of an injectable sustained-release formulation of morphine: antinociceptive properties in rats | Q42540087 |
| | Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. | Q42554140 |
| | Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study | Q42613528 |
| | Early clinical experience with the novel NMDA receptor antagonist CNS 5161. | Q42780410 |
| | Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists | Q43070644 |
| | NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up. | Q43263858 |
| | Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats | Q43557540 |
| | HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test | Q43791861 |
| | Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer | Q43838691 |
| | Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients | Q43846957 |
| | Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception | Q44106429 |
| | Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine | Q44108743 |
| | COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease | Q44182620 |
| | A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. | Q44193387 |
| | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis | Q44193431 |
| | Morphine tolerance in mice changes response of heroin from mu to delta opioid receptors | Q44331563 |
| | Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo | Q44331812 |
| | Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: Relationship to receptor selectivity | Q44334204 |
| | Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine | Q44343593 |
| | Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice | Q44343619 |
| | Opioids, confusion and opioid rotation | Q44348962 |
| | Sequence Variability and Candidate Gene Analysis in Two Cancer Patients with Complex Clinical Outcomes During Morphine Therapy | Q44403651 |
| | Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: a randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated pat | Q44415313 |
| | N‐terminal modifications leading to peptide ORL1 partial agonists and antagonists | Q44609842 |
| | Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences | Q44706338 |
| | Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting | Q44719380 |
| | Norepinephrine and pain | Q44737077 |
| | A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain | Q44741324 |
| | The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor | Q44779669 |
| | The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation | Q44791007 |
| | The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers | Q44808681 |
| | Drugs in palliative care: results from a representative survey in Germany | Q44815756 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pain management | Q621261 |
| | cancer pain | Q3712728 |
| P304 | page(s) | 151-171 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging analgesics in cancer pain management | |
| P478 | volume | 10 | |